Galderma, a part of Nestlé Skin Health and a global leader in dermatology, has forayed into therapeutic hair care category in India.
The Indian arm of the company has introduced Qilib, a new range of advanced hair retention botanical formulation to prevent hair fall and restore hair in both men and women.
“Qilib is an innovative solution, clinically proven with multiple clinical trials and is a safe product for the treatment of hair fall. It uses a combination of four key natural ingredients with a three way action which reduces hair shedding in 45 days and new strands grow as early as 90 days,” G. Sathya Narayanan, Managing Director, Galderma South Asia told The Hindu .
According to dermatologists, excessive hair shedding and thinning are caused due to various factors mainly due to stress, smoking, insomnia, post-child birth, pollution, malnutrition or extreme dieting, infectious diseases or acute febrile illness and hair coloration or styling.
Humans have 90,000 to 150,000 hair on the scalp and in healthy state, approximately 85 per cent of scalp hair follicles are in the growing phase while 15 per cent are in the resting phase which is followed by shedding of old hair and growth of new hair in a sequential manner.
Normally, 25 to 100 hairs are shed daily and most shedding goes unnoticed. However, excessive hair shedding or episodic hair fall has now become common among people resulting in demand for hair care solutions.
“The therapeutic hair care category is valued at Rs. 250 crore in India and growing at 20 per cent a year. Our aim is to achieve a market share of 10 per cent and be among the top five players in this category,” Mr. Narayanan added.
The company will roll out more products in the coming months from its global portfolio.
He said that the company’s offerings in the pigmentation category have been doing well.
Last year the company had launched BI-LUMA, a formulation to deal with dark patches and unevenness of the skin that surface due to various hyperpigmentary disorders.
Galderma India which has already acquired five per cent market share of this Rs 450 crore segment called Demelanising agents, is now eyeing eight per cent market share, he said.
Meanwhile, the BI-LUMA has won Dr HR Nanji Memorial Organization of Pharmaceutical Producers of India (OPPI) Marketing Excellence Award in the category of Best New Pharmaceutical Introduction.
“The award is in recognition of Galderma’s commitment towards dermatology benefiting many patients across India,” Mr Narayanan said.
